Technical Analysis for SRPT - Sarepta Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 1,2,3 Pullback Bullish | Bullish Swing Setup | 0.00% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| Multiple of Ten Bullish | Other | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Bearish Engulfing | Bearish | -0.21% | |
| Slingshot Bullish | Bullish Swing Setup | -0.21% | |
| Multiple of Ten Bullish | Other | -0.21% | |
| Shooting Star Candlestick | Bearish | -2.75% | |
| Reversal New Highs Setup | Bullish Swing Setup | -2.75% |
| Alert | Time |
|---|---|
| Possible Inside Day | about 4 hours ago |
| 10 DMA Support | about 5 hours ago |
| Down 2 % | about 8 hours ago |
| Down 1% | about 8 hours ago |
| Fell Below 10 DMA | about 8 hours ago |
Get a Trading Assistant
- Earnings date: 06/06/2024
Sarepta Therapeutics, Inc. Description
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. Its lead product candidate is eteplirsen, an antisense PMO-based therapeutic, which is in Phase IIb clinical development for the treatment of individuals with Duchenne muscular dystrophy. The company is also involved in developing treatments that are in Phase I clinical trials for infectious diseases, including AVI-7288 for Marburg virus; and AVI-7100 for H1N1 influenza virus. In addition, it focuses on developing preclinical research product candidates for the treatment of other neuromuscular, infectious, and rare diseases. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Biology Clinical Development Infectious Diseases Rare Diseases Clinical Research Influenza Dystrophy Muscular Dystrophy Duchenne Muscular Dystrophy Duchenne Therapeutic Gene Modulation Antisense RNA
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 159.89 |
| 52 Week Low | 55.25 |
| Average Volume | 909,110 |
| 200-Day Moving Average | 112.79 |
| 50-Day Moving Average | 125.43 |
| 20-Day Moving Average | 125.48 |
| 10-Day Moving Average | 131.54 |
| Average True Range | 5.34 |
| RSI (14) | 60.16 |
| ADX | 36.55 |
| +DI | 36.84 |
| -DI | 10.06 |
| Chandelier Exit (Long, 3 ATRs) | 130.65 |
| Chandelier Exit (Short, 3 ATRs) | 130.40 |
| Upper Bollinger Bands | 139.29 |
| Lower Bollinger Band | 111.67 |
| Percent B (%b) | 0.75 |
| BandWidth | 22.01 |
| MACD Line | 2.65 |
| MACD Signal Line | 1.58 |
| MACD Histogram | 1.0693 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 138.16 | ||||
| Resistance 3 (R3) | 137.87 | 135.63 | 137.18 | ||
| Resistance 2 (R2) | 135.63 | 134.14 | 135.77 | 136.86 | |
| Resistance 1 (R1) | 133.97 | 133.22 | 132.85 | 134.25 | 136.53 |
| Pivot Point | 131.73 | 131.73 | 131.17 | 131.87 | 131.73 |
| Support 1 (S1) | 130.06 | 130.23 | 128.94 | 130.35 | 128.07 |
| Support 2 (S2) | 127.82 | 129.31 | 127.96 | 127.74 | |
| Support 3 (S3) | 126.16 | 127.82 | 127.42 | ||
| Support 4 (S4) | 126.44 |
